Patents Issued in September 24, 2024
  • Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
    Patent number: 12098155
    Abstract: The disclosure is directed to new crystalline tebipenem pivoxil salt forms, including a crystalline tebipenem pivoxil ethane sulfonate salt form (Form A), a crystalline tebipenem pivoxil ketoglutarate salt form (Form A), tebipenem pivoxil maleate salt forms (Form A and Form B), a tebipenem pivoxil malate salt form (Form A), a tebipenem pivoxil methane sulfonate salt form (Form B), a tebipenem pivoxil hydrobromide salt form (Form B), and a tebipenem pivoxil edisylate salt form (Form A). The disclosure also includes a composition, comprising a crystalline tebipenem pivoxil salt and a pharmaceutically acceptable carrier and further includes a method for treating an antibiotic resistant bacterial infection, comprising administering to a patient in need of such treatment a therapeutically effective amount of a crystalline tebipenem pivoxil salt.
    Type: Grant
    Filed: June 9, 2023
    Date of Patent: September 24, 2024
    Assignee: SPERO THERAPEUTICS, INC.
    Inventors: Akash Jain, Evan Hecker, Richard Edwards, Thierry Bonnaud
  • Compound and organic light emitting device comprising the same
    Patent number: 12098156
    Abstract: Provided is a compound of Chemical Formula 1: wherein: X1 to X6 are each independently CH or N, provided that at least one of X1 to X6 is N; Ar1 to Ar4 are each independently a substituted or unsubstituted: C6-60 aryl or C2-60 heteroaryl containing one or more of N, O, and S, provided that at least one of Ar1 to Ar4 is any one of: R2 is hydrogen, deuterium, or a substituted or unsubstituted: C6-60 aryl or C2-60 heteroaryl containing one or more of N, O and S; each R3 is independently hydrogen, deuterium, or a substituted or unsubstituted: C6-60 aryl or C2-60 heteroaryl containing one or more of N, O, and S; each R1 is independently hydrogen, deuterium, or a substituted or unsubstituted: C6-60 aryl or C2-60 heteroaryl containing one or more of N, O and S; and n is an integer of 0 to 8, and organic light emitting devices including the same.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: September 24, 2024
    Assignee: LG Chem, Ltd.
    Inventors: Min Woo Jung, Dong Hoon Lee, Boon Jae Jang, Wanpyo Hong, Sang Duk Suh, Jungha Lee, Su Jin Han, Seulchan Park, Sunghyun Hwang
  • Organic electroluminescent materials and devices
    Patent number: 12098157
    Abstract: The present invention includes a series of novel osmium bis(tridenatate) complexes with emission profiles in the near-infrared region.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: September 24, 2024
    Inventors: Jui-Yi Tsai, Alexey Borisovich Dyatkin, Zhiqiang Ji, Paul M. Lahti, Miguel A. Esteruelas, Ana M. Lopez, Enrique Onate, Ainhoa San Torcuato, Pierre-Luc T. Boudreault
  • Transition metal compound, catalyst composition and method for preparing polypropylene using the same
    Patent number: 12098158
    Abstract: The present disclosure relates to a novel transition metal compound of the following Chemical Formula 1, which exhibits high hydrogen reactivity with excellent catalytic activity for propylene polymerization, and is useful in the preparation of a polypropylene having a narrow molecular weight distribution and a low melting point, a catalyst composition including the same, and a method for preparing a polypropylene using the same, wherein M, X1, X2, R1 to R9 are described herein.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: September 24, 2024
    Assignee: LG Chem, Ltd.
    Inventors: Insun Lee, Seok Hwan Kim, Byung Seok Kim, Donghyeon Gwon, Sangjin Jeon, Seyoung Kim
  • Solid forms of substituted benzoxaborole and compositions thereof
    Patent number: 12098159
    Abstract: The present invention relates to solid forms of a substituted benzoxaborole compound, specifically crystalline forms of a compound of formula I, compositions comprising crystalline forms of the compound of formula (I), and methods of their use.
    Type: Grant
    Filed: January 9, 2023
    Date of Patent: September 24, 2024
    Assignee: 5Metis, Inc.
    Inventors: Chun Yu Liu, Marissa Caroline Aubrey, Yong-Kang Zhang, Michael Samuels
  • Organometallic chain transfer agents
    Patent number: 12098160
    Abstract: Embodiments relate to organometallic compositions that are useful for chain transfer during olefin polymerization. Such compositions are chain transfer agents comprising an organoaluminum compound of the formula Al(CH2CH(Y2)A2)3 and an organozinc compound of the formula Zn(CH2CH(Y2)A2)2.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: September 24, 2024
    Assignee: Dow Global Technologies LLC
    Inventors: Lixin Sun, Endre Szuromi, Edmund M. Carnahan
  • Programmable polymeric drugs
    Patent number: 12098161
    Abstract: Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I): or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, L, L1, L2, L3, M and n are as defined herein. Methods associated with preparation and use of such compounds is also provided.
    Type: Grant
    Filed: March 9, 2022
    Date of Patent: September 24, 2024
    Assignee: SONY GROUP CORPORATION
    Inventors: Tracy Matray, Sharat Singh, C. Frederick Battrell, Michael Vanbrunt
  • Neutral glycosylated amides and dianionic glucuronidated acids as stabilizers for biological molecules
    Patent number: 12098162
    Abstract: The compounds of the present invention are useful for stabilizing biological molecules, particularly in the presence of pH and thermal stress.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: September 24, 2024
    Assignee: EXTREMOCHEM, LDA
    Inventors: Eva Correia Lourenço, Osvaldo Ascenso
  • Method for producing functional crystalline sweetener
    Patent number: 12098163
    Abstract: The present invention relates to a method for preparing a crystalline functional sweetener, and more specifically, relates to a method for preparing a crystalline functional sweetener for raising the crystallization yield and increasing the particle size by controlling the content of impurities or production of impurities comprised in a solution for preparing the crystal.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: September 24, 2024
    Assignee: SAMYANG CORPORATION
    Inventors: Go-Eun Kim, Jae-Kyung Yang, Kyung-Hun Ryu, Sung Won Park, Ji Won Park, Eunsoo Cho
  • Non-immunogenic protein nanoparticles with cancer targeting activity using albumin-binding peptide
    Patent number: 12098164
    Abstract: The present invention relates to recombinant self-assembling protein nanoparticles presenting an albumin-binding peptide at the surface. For the recombinant self-assembling protein nanoparticles according to the present invention, an albumin-binding peptide can reduce the immunogenicity of the recombinant self-assembling protein nanoparticles because the albumin-binding peptide is presented at the surface, and thus binds to an albumin protein present in vivo, and the albumin-binding peptide can also provide the cancer delivery function of the recombinant self-assembling protein nanoparticles because the albumin-binding peptide binds to albumin around cancer. Simultaneously, the binding of the albumin-binding peptide to albumin can significantly increase the in vivo residence time of the recombinant self-assembling protein nanoparticles, thus increasing the potential for use in various medical applications.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: September 24, 2024
    Assignee: CELLEMEDY CO., LTD
    Inventors: Jeewon Lee, Bo Ram Lee
  • Mature virus-like particles of flaviviruses
    Patent number: 12098165
    Abstract: Modified and expressed virus-like particles are described that are capable of eliciting immune response in a mammal upon administrating a pharmaceutically efficient dosage to the mammal. The virus-like particle comprises a modified form of M and E structural proteins of flavivirus. Further, the virus-like particle comprises an amino acids sequence substantially corresponding to a sequence set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, wherein conserved and internally located His at multiple positions of the M and E proteins are substituted with uncharged residues, and other secretion-enhancing substitutions are introduced.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: September 24, 2024
    Assignees: Chiang Mai University, National Science and Technology Development Agency (NSTDA)
    Inventors: Nopporn Sittisombut, Malinee Sae-Lim, Nicha Charoensri, Poonsook Keelapang
  • Immunogenic composition against avian influenza virus H5 subtype
    Patent number: 12098166
    Abstract: The invention relates to the field of veterinary medicine. The invention provides an immunogenic composition, comprising a hemagglutinin protein of avian influenza virus H5 subtype. Also provided is a method of differentiating animals naturally infected with AIV from animals vaccinated with the immunogenic composition of the invention. The immunogenic composition of the invention can provide a broader, more effective, long-lasting and early onset protection on poultry.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: September 24, 2024
    Assignee: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: Egbert Siegfried Mundt, Xiaoping Cui, Zenglei Hu
  • Self-assembled nanoparticle containing gB protein of EB virus and preparation method and use thereof
    Patent number: 12098167
    Abstract: The present invention is related to a self-assembled nanoparticle containing a gB protein of an EB virus and a preparation method and use thereof. The self-assembled nanoparticle comprises a first polypeptide and a second polypeptide; the first polypeptide comprises the gB protein and a first vector subunit, the second polypeptide comprises a second vector subunit; the first vector subunit is I53-50A1, and the second vector subunit is I53-50B.4PT1. In the self-assembled nanoparticle, the gB protein of the EB virus is displayed on the surface of the nanoparticle for the first time. The particle size of the self-assembled nanoparticle is larger than that of the antigen gB, and the chemical stability of the self-assembled nanoparticle is higher than that of the antigen gB, and the binding capacity with the neutralizing antibody of the self-assembled nanoparticle are higher than that of the antigen gB.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: September 24, 2024
    Assignees: SUN YAT-SEN UNIVERSITY, SUN YAT-SEN UNIVERSITY CANCER CENTER (SYSUCC)
    Inventors: Musheng Zeng, Cong Sun, Yixin Zeng, Guokai Feng, Yinfeng Kang, Xinchun Chen, Xiao Zhang, Qianying Zhu, Jiangping Li, Xiangwei Kong
  • XylR mutant for improved xylose utilization or improved co-utilization of glucose and xylose preliminary
    Patent number: 12098168
    Abstract: The disclosure relates to mutant gene(s) that confer upon microorganisms that express them an improved capacity to utilize xylose and improved capacity to co-utilize glucose and xylose thereby resulting in improved growth of the microorganism. Further encompassed are methods of producing fatty acids and fatty acid derivatives from cellulosic biomass, xylose, and/or a glucose/xylose mix by employing the host cells expressing the engineered XylR variants and compositions of biologically produced fatty acids and fatty acid derivatives.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: September 24, 2024
    Assignee: Genomatica, Inc.
    Inventors: Stephen Thomas Payne, Scott Allen Frykman, Bernardo Moura Torres Da Costa, Isolde Callihan, Sankaranarayanan Venkiteswaran, Leland Ken Wong
  • neurotoxin (BoNT/EN) and derivatives thereof
    Patent number: 12098169
    Abstract: Provided herein is a novel homolog of Clostridial botulinum neurotoxin (BoNT) identified in the bacterial species Enterococcus faecium (BoNT/EN). BoNT/EN variants and chimeric toxins comprising domains from BoNT/EN and other BoNTs are also provided. Further provided herein are methods of producing BoNT/EN and its use, e.g., in therapeutic applications.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: September 24, 2024
    Assignee: Children's Medical Center Corporation
    Inventors: Min Dong, Paul Stenmark, Sicai Zhang, Andrew Doxey
  • Surface layer protein a (SlpA) as a therapeutic agent for the treatment of inflammatory diseases
    Patent number: 12098170
    Abstract: The current invention provides a recombinant bacterium, the recombinant bacterium being genetically modified to synthesize surface layer protein A (SlpA). Efficacious therapies for a subject suffering from an inflammation mediated disease are also provided. The methods of the current invention comprise administering to a subject in need thereof a therapeutically effective amount of the recombinant bacterium, for example L. lactis cells, or a therapeutically effective amount of the isolated SlpA. The recombinant bacteria cells or SlpA isolated from the recombinant bacteria can be in a pharmaceutical composition comprising a pharmaceutically acceptable carrier and/or excipient.
    Type: Grant
    Filed: June 10, 2022
    Date of Patent: September 24, 2024
    Assignees: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED, RISE THERAPEUTICS, LLC
    Inventors: Bikash Sahay, Gary Fanger, Jyoti Jha, Christian Furlan Freguia
  • Hybrid sugar transporters with altered sugar transport activity and uses thereof
    Patent number: 12098171
    Abstract: The present invention provides for a hybrid sugar transporter having an altered sugar transporter activity and comprising at least a first transmembrane domain (TMD) from a first sugar transporter and a second TMD from a second sugar transporter, wherein the first sugar transporter and the second sugar transporter are heterologous to each other.
    Type: Grant
    Filed: December 10, 2021
    Date of Patent: September 24, 2024
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Michelle A. O'Malley, Igor A. Podolsky, Susanna Seppala
  • Compositions and methods for targeting MASAs to treat cancers with spliceosome mutations
    Patent number: 12098172
    Abstract: The present disclosure relates to compositions and methods for treating cancers. In particular, the present disclosure provides materials and methods for identifying mis-splicing-associated surface antigens (MASAs) generated by altered spliceosome proteins, as well as materials and methods for targeting cancerous tumors expressing MASAs.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: September 24, 2024
    Assignee: The Johns Hopkins University
    Inventors: William Brian Dalton, Ben Ho Park, Eric Christenson
  • Innocuous, structured scaffolds for structure-based amyloid disease vaccines and antigens
    Patent number: 12098173
    Abstract: The present disclosure relates generally to polypeptides, which may be used of the treatment of neurological diseases or disorders.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: September 24, 2024
    Assignee: The Governors of the University of Alberta
    Inventors: Holger Wille, Jiarui Fang, José Miguel Flores-Fernández, Vineet Rathod, Xinli Tang
  • Oct-3/4 variant
    Patent number: 12098174
    Abstract: The present invention provides an Oct-3/4 protein variant wherein lysine at position 156; lysine at position 286; or lysines at positions 156 and 286 in the Oct-3/4 protein is (are) substituted with arginine. The Oct-3/4 protein variant according to the present invention can inhibit a protein degradation mechanism through ubiquitination, and shows a higher half-life, compared to the wild-type Oct-3/4, thereby exhibiting high stability.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: September 24, 2024
    Assignee: CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Kwang-Hyun Baek, Ji-Hye Choi
  • Peptide inhibitors targeting the CXCL12/HMGB1 interaction and uses thereof
    Patent number: 12098175
    Abstract: The present invention provides novel peptides binding to HMGB1 and inhibiting the interaction of HMGB1 and CX-CL12. The present invention also provides proteins, virus-like particles, nanoparticles and compositions comprising such peptides and nucleic acids encoding such peptides. In addition, methods for using the peptides are provided. In particular, the peptides are useful in the treatment of inflammation and immune-related diseases.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: September 24, 2024
    Assignee: INSTITUTE FOR RESEARCH IN BIOMEDICINE
    Inventors: Andrea Cavalli, Jacopo Sgrignani, Mariagrazia Uguccioni
  • Keratin BD-4, preparation method, and pharmaceutical composition and use thereof
    Patent number: 12098176
    Abstract: Provided are keratin BD-4, an encoding nucleic acid molecule thereof, an expression vector, a host cell, and a pharmaceutical composition containing the keratin. The keratin BD-4 can be used for preparing drugs having antipyretic and analgesic, antitussive and expectorant, and antiepileptic effects.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: September 24, 2024
    Assignee: Institute of Materia Medica, Chinese Academy of Medical Sciences
    Inventors: Shishan Yu, Xiaoliang Wang, Jing Qu, Mi Li, Guozhu Su, Ling Wang, Jie Cai, Shaofeng Xu, Jiang Fu
  • Targeted IL-12 treatments and methods to stimulate haNK and NK92mi cells
    Patent number: 12098177
    Abstract: Compositions and methods for NK cell based treatments, and particularly NK cells that express and intracellularly retain IL-2, are presented in which the NK cells are stimulated with a chimeric protein that has a cancer cell targeting portion and an IL-12 portion. Beneficially, such chimeric protein has substantially reduced systemic toxicity and induces IFN-? secretion in a targeted manner. Moreover, chimeric proteins contemplated herein also significantly enhanced IFN-? secretion in NK cells that express and intracellularly retain IL-2 as compared to native NK cells. Preferred chimeric proteins comprise SEQ ID NO:1 or SEQ ID NO:2, and SEQ ID NO:3.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: September 24, 2024
    Assignee: NantBio, Inc.
    Inventors: Kayvan Niazi, Clifford Anders Olson, Shiho Tanaka, Heather McFarlane
  • Methods of using interleukin-2 agents
    Patent number: 12098178
    Abstract: IL-2 agents that comprise IL-2 variants are disclosed as well as methods, compositions, and uses thereof. The IL-2 agents described herein can be used to treat and/or prevent various disorders and conditions.
    Type: Grant
    Filed: December 3, 2021
    Date of Patent: September 24, 2024
    Assignees: Visterra, Inc., The General Hospital Corporation
    Inventors: Scott Moore Carlson, Gregory Babcock, Zachary Shriver, Boopathy Ramakrishnan, Thiago de Jesus Borges, Leonardo Vidal Riella
  • Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
    Patent number: 12098179
    Abstract: Despite the notion that human CD8+ T cells are the final mediators of autoimmune ?-cell destruction in type 1 diabetes (T1D), none of their target epitopes has been demonstrated to be naturally processed and presented by ? cells. The inventors therefore performed an epitope discovery study combining HLA Class I peptidomics and transcriptomics strategies. Inflammatory cytokines increased ?-cell peptide presentation in vitro, paralleling upregulation of HLA Class I expression. Peptide sources included known ?-cell antigens and several insulin granule proteins. Urocortin 3 was identified as a novel ?-cell antigen, which was processed into HLA-A2- and HLA-A3-restricted epitopes recognized by circulating naive CD8+ T cells in type 1 diabetic and healthy donors. Accordingly, the present invention relates to antigenic peptides derived from urocortin-3 and uses thereof for the diagnosis and treatment of T1D.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: September 24, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS
    Inventors: Roberto Mallone, Sergio Gonzalez-Duque, Yann Verdier, Marie-Eliane Azoury, Georgia Afonso, Joëlle Vinh
  • Compositions and uses of vasoactive intestinal peptide (VIP) antagonists
    Patent number: 12098180
    Abstract: This disclosure relates to VIP antagonist for uses in managing the treatment or prevention of cancer and viral infections. In certain embodiments, this disclosure relates to chimeric variants of VIP antagonists, as peptides disclosed herein, and pharmaceutical composition comprising the same. In certain embodiments, this disclosure contemplates methods of stimulating immune cells to target cancer by mixing immune cells in vitro with peptides disclosed herein and further administering an effective amount of stimulated immune cells to a subject in need of cancer treatment.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: September 24, 2024
    Assignee: Emory University
    Inventors: Edmund K. Waller, Yiwen Li, Sruthi Ravindranathan, Jian-Ming Li
  • High throughput cloning of paired bipartite immunoreceptor polynucleotides and applications thereof
    Patent number: 12098181
    Abstract: Provided herein are compositions and methods for high throughout cloning of fused bipartite immunoreceptor polynucleotides encoding cognate pairs of bipartite immunoreceptors. Also provided herein are various applications of the fused bipartite immunoreceptor polynucleotides, expression vectors containing the fused bipartite immunoreceptor polynucleotides, or cells containing the fused bipartite immunoreceptor polynucleotides or expression vectors.
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: September 24, 2024
    Assignee: RootPath Genomics, Inc.
    Inventors: Xi Chen, Ely Porter
  • Polypeptides, cells, and methods involving engineered CD16
    Patent number: 12098182
    Abstract: This disclosure describes, generally, a modified form of CD16, genetically-modified cells that express the modified CD16, and methods that involve the genetically-modified cells. The modified form of CD16 can exhibit increased anti-tumor and/or anti-viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: September 24, 2024
    Assignee: Regents of the University of Minnesota
    Inventors: Bruce Kenneth Walcheck, Dan Samuel Kaufman, Jianming Wu, Yawu Jing, Zhenya Ni
  • Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
    Patent number: 12098183
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: September 24, 2024
    Inventors: Heiko Schuster, Janet Peper, Kevin Röhle, Philipp Wagner, Hans-Georg Rammensee
  • G protein-coupled receptor (GPCR) ligand assay
    Patent number: 12098184
    Abstract: The systems and methods described herein include the use of Giant Plasma Membrane Vesicles (GPMVs) derived from cells expressing SPASM sensors (e.g., SPASM GPCR sensors). Herein provided are giant plasma membrane vesicle (GPMV) sensors containing a membrane-associated polypeptide, where the membrane-associated polypeptide contains a target G protein-coupled receptor (GPCR), a linker including an amino acid sequence flanked by a FRET donor and a FRET acceptor, and a receptor partner for the target GPCR, where the linker separates the target GPCR from the receptor partner. In another aspect, provided is a method for quantifying the intrinsic efficacy of a compound for a target GPCR. In another aspect, provided is a method for identifying a compound that interacts with a target GPCR.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: September 24, 2024
    Assignee: Regents of the University of Minnesota
    Inventors: Sivaraj Sivaramakrishnan, Keehun Kim
  • Monoclonal antibody 11B2C7 or fragment thereof, that specifically recognizes herpes simplex virus 1 and 2
    Patent number: 12098185
    Abstract: The present invention refers to a new monoclonal antibody or fragment thereof, called 11B2C7, which specifically recognizes herpes simplex virus (HSV), in its two types, herpes simplex virus type 1 and herpes simplex virus type 2 (HSV-1 and HSV-2). Preferably, the antibody of the invention is useful for the development of methods for the diagnosis of herpes simplex virus infection, as well as for the production of pharmaceutical compositions intended for the treatment, protection and/or prophylaxis of infection specifically caused by HSV-1 and HSV-2.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: September 24, 2024
    Assignees: PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE, FUNDACION COPEC UNIVERSIDAD CATÓLICA
    Inventors: Alexis Kalergis Parra, Susan Bueno Ramírez, Pablo Gonzalez Muñoz
  • Multivalent anti-SARS-CoV-2 nanobodies
    Patent number: 12098186
    Abstract: Provided herein are asymmetric biparatopic neutralizing nanobody-based antibodies which engage SARS-2 spike in at least two independent epitopes. Several biparatopic constructs showed synergy in neutralizing viral infection of cells. Data also showed that single biparatopic constructs are more effective than the combination of the parental monotopic constructs were at neutralization. The nanobodies that were identified in an initial screen of a large and highly diverse library bind to a single epitope that overlaps with the ACE2 binding site.
    Type: Grant
    Filed: June 30, 2022
    Date of Patent: September 24, 2024
    Assignee: National Technology & Engineering Solutions of Sandia, LLC
    Inventors: Brooke Nicole Harmon, Le Thanh Mai Pham, Yooli Kim Light, Christine Elizabeth Thatcher, Maxwell Stefan
  • Bispecific HIV-1-neutralizing antibodies
    Patent number: 12098187
    Abstract: In various embodiments, the present invention relates generally to using bispecific antibodies in the prevention and treatment of HIV.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: September 24, 2024
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: David D. Ho, Yaoxing Huang, Jian Yu
  • Antibody fragments for the treatment of biofilm-related disorders
    Patent number: 12098188
    Abstract: This disclosure provides antibody fragments and isolated polypeptides comprising the antibody fragments that are useful as a therapeutic for those with an existing infection characterized by the formation of biofilms. Antibody fragments and isolated polypeptides comprising the antibody fragments can be administered to detect, treat, or prevent infection and/or remediate biofilms. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system and/or traditional antibiotics.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: September 24, 2024
    Assignee: Research Institute at Nationwide Children's Hospital
    Inventors: Lauren O. Bakaletz, Steven D. Goodman
  • Composition and method for the diagnosis and treatment of iron-related disorders
    Patent number: 12098189
    Abstract: Provided herein are methods of using the antibodies that bind to RGMc to treat and diagnose iron-related disorders.
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: September 24, 2024
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Bernhard Mueller, Andreas Popp, Jennifer M. Perez
  • Humanized anti-C5 antibodies and uses thereof
    Patent number: 12098190
    Abstract: This invention relates to inhibition of the complement signaling using an anti-C5 antibody. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5 antibody.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: September 24, 2024
    Assignees: The Trustees of the University of Pennsylvania and, Kira Pharmaceuticals (US) LLC
    Inventors: Wenchao Song, Takashi Miwa, Damodar Gullipalli, Ping Tsui, Sayaka Sato
  • Antibodies to amyloid beta
    Patent number: 12098191
    Abstract: Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease.
    Type: Grant
    Filed: February 16, 2022
    Date of Patent: September 24, 2024
    Assignee: MEDIMMUNE LIMITED
    Inventors: Maria Groves, Suzanne Gustavsson, Kina Höglund, Chris Lloyd, Adrian Nickson, Camilla Niva, Sylvia Simon, David Lowne, Fraser Welsh, Per-Ola Freskgard
  • Composition and method for the diagnosis and treatment of iron-related disorders
    Patent number: 12098192
    Abstract: Provided herein are methods of using the antibodies that bind to RGMc to treat and diagnose iron-related disorders.
    Type: Grant
    Filed: April 17, 2024
    Date of Patent: September 24, 2024
    Assignees: AbbVie Deutschland Gmbh & Co. KG, AbbVie Inc.
    Inventors: Bernhard Mueller, Andreas Popp, Jennifer M. Perez
  • Netrin G1 as a biomarker for enhancing tumor treatment efficacy
    Patent number: 12098193
    Abstract: The present disclosure provides methods of inducing desmoplastic stroma to express a normal phenotype by detecting increased levels of NetG1 or NGL1 in tumor or in desmoplastic stroma isolated from a human subject, and/or detecting NetG1 in circulating extracellular vesicles, and/or detecting increased pFAK in the stroma, and treating the human subject with a therapeutic regimen; and by detecting NetG1 in a microvesicle isolated from a human subject, and/or treating the human subject with a therapeutic regimen.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: September 24, 2024
    Assignee: Institute For Cancer Research
    Inventors: Edna Cukierman, Ralph Francescone, Janusz Franco-Barraza, Kristopher Raghavan
  • Bone-targeting antibodies
    Patent number: 12098194
    Abstract: Provided are recombinant and chemically-conjugated antibodies and fragments thereof modified with one or more poly-aspartate (poly-D) peptides (e.g., a D10 sequence) to improve localization of the antibodies or fragments to bone. Methods of making and using of these antibodies and fragments also are disclosed.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: September 24, 2024
    Assignee: Genzyme Corporation
    Inventors: Huawei Qiu, Sunghae Park, James Stefano
  • Anti-IL-23p19 antibody and use thereof in treating diseases
    Patent number: 12098195
    Abstract: The present invention relates to a novel antibody and an antibody fragment thereof that specifically bind to IL-23p19 and a composition comprising the antibody or the antibody fragment thereof. In addition, the present invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell comprising the nucleic acid, and related use. Furthermore, the present invention relates to therapeutic and diagnostic use of the antibody and the antibody fragment.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: September 24, 2024
    Assignee: INNOVENT BIOLOGICS (SUZHOU) CO., LTD.
    Inventors: Junjian Liu, Min Wu, Li Li, Shuaixiang Zhou, Enkun Zhou
  • Production of biosimilar ustekinumab in CHO cells
    Patent number: 12098196
    Abstract: The present invention relates to a method for producing an ustekinumab antibody in CHO cells. It further relates to the use of the produced antibody in the treatment of plaque psoriasis, psoriatic arthritis and inflammatory bowel disease.
    Type: Grant
    Filed: April 24, 2023
    Date of Patent: September 24, 2024
    Assignee: FYB202 Project GMBH
    Inventors: Susanne Pippig, Carsten Brockmeyer
  • Polypeptides comprising immunoglobulin chain variable domains which bind to interleukin-6 receptor (IL-6R) and methods of use thereof to treat autoimmune and inflammatory diseases
    Patent number: 12098197
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-6R, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: September 24, 2024
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Tim Carlton, Marion Cubitt, Kevin Roberts, Luana Maggiore, Mike West, Keith Ray
  • Antibody binding specifically to ECL-2 of claudin 3, fragment thereof, and use thereof
    Patent number: 12098198
    Abstract: The invention of the present application relates to a use of an antibody binding specifically to ECL-2 of claudin 3 and functional fragments thereof in cancer cell detection, diagnosis, imaging, and application to cancer treatment (anticancer use of the antibody itself, and application to ADC and CAR-expression cells (particularly immune cells)), an antibody that includes a characteristic CDR sequence exerting a remarkable effect in such uses, and a functional fragment thereof.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: September 24, 2024
    Assignee: ABION INC.
    Inventors: Young Kee Shin, Sung Youl Hong, Young Deug Kim, Jun Young Choi, Heo Bin Yang, Ha Yeon Park, Sung Su Kim
  • Immunologic effector cell of targeted CLD18A2, and preparation method and use thereof
    Patent number: 12098199
    Abstract: Disclosed are a chimeric antigen receptor (CAR) targeting CLD18A2, and preparation method and use thereof. The extracellular binding region of the CAR comprises a protein specifically recognizing CLD18A2. The immune effector cell modified by the CAR can be used to treat tumors such as pancreatic cancer and stomach cancer.
    Type: Grant
    Filed: November 9, 2021
    Date of Patent: September 24, 2024
    Assignee: CRAGE MEDICAL CO., LIMITED
    Inventors: Huamao Wang, Bo Song, Xiumei Cai
  • Brain-targeting single domain antibodies and purification methods
    Patent number: 12098200
    Abstract: Provided herein are single domain antibodies (sdAbs) configured for passing the blood brain barrier in a human or mammal brain. Methods of using such sdAbs are also described herein, such as methods of binding to brain cells, binding with and transporting other sdAbs with beneficial functionalities, binding to and transporting biochemical or pharmaceutical species with beneficial functionalities, and treating, diagnosing, or prophylactically treating a disease, malignancy, or condition.
    Type: Grant
    Filed: October 12, 2022
    Date of Patent: September 24, 2024
    Assignee: National Technology & Engineering Solutions of Sandia, LLC
    Inventors: Brooke Nicole Harmon, Maxwell Stefan, Jennifer Schwedler, Christopher Sumner, Yooli Kim Light, Catherine Margaret Mageeney
  • Anti-TIM3 monoclonal antibodies and chimeric antigen receptors
    Patent number: 12098201
    Abstract: Antibodies, fragments thereof, and chimeric proteins comprising the same are presented that have specific binding activity against T-cell immunoglobulin mucin receptor 3 (TIM3). Advantageously, contemplated molecules can be used in pharmaceutical compositions for immune therapy, particularly in individuals receiving cancer vaccines and/or checkpoint inhibitor treatment.
    Type: Grant
    Filed: April 18, 2023
    Date of Patent: September 24, 2024
    Assignee: NantBio, Inc.
    Inventors: Clifford Anders Olson, Kayvan Niazi, Hermes J. Garban, Raymond Wong, Shiho Tanaka
  • Non-cytotoxic modified cells and use thereof
    Patent number: 12098202
    Abstract: Modified cells comprising a transmembrane polypeptide comprising at least one extracellular target receptor-binding domain, a transmembrane domain and an intracellular domain, wherein the intracellular domain is not capable of transducing any signal are provided. Methods of inducing or inhibiting signaling by a target receptor in a target cell comprising contacting the target cell with a modified cell of the invention are also provided.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: September 24, 2024
    Assignee: THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD.
    Inventors: Alon Monsonego, Angel Porgador, Roee Atlas
  • Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA
    Patent number: 12098203
    Abstract: This invention relates to a hetero-dimeric multi-specific format of multiple antibody variable domains comprising a core of two split variable domain pairs wherein both variable light domains and the two cognate variable heavy domains are positioned in tandem on two separate protein chains, respectively, and wherein one of said variable domain pairs is specific for human serum albumin and the other said variable domain pair is specific for human CD3.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: September 24, 2024
    Assignee: Numab Therapeutics AG
    Inventors: David Urech, Tea Gunde, Sebastian Meyer, Christian Hess, Alexandre Simonin
  • Humanized anti-human PD-L1 monoclonal antibody and preparation method therefor and use thereof
    Patent number: 12098204
    Abstract: The present invention relates to a humanized anti-human PD-L1 monoclonal antibody, and a preparation method and use thereof. The humanized anti-human PD-L1 monoclonal antibody provided in the present invention has high affinity and specificity for PD-L1, stimulates T cells to secrete cytokines, and specifically relieves the negative immune regulation by PD-L1. The effect of this antibody is not achieved by directly blocking the interaction between PD-1 and PD-L1, presenting a new mechanism of immune checkpoint regulation. Therefore, the functional humanized anti-human PD-L1 monoclonal antibody provided in the present invention activates T cells by regulating the PD-L1 signaling pathway, thereby achieving the purpose of tumor immunotherapy.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: September 24, 2024
    Assignee: Nanjing Genscript Biotech Co., Ltd.
    Inventors: Liusong Yin, Tielin Zhou, Zhuo Fang, Yanling Mi, Chunchen Wu